BERKELEY HEIGHTS, N.J., May 19, 2011 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), announced today that new interim data from an ongoing, multicenter, Phase 1/2 clinical trial of oral sapacitabine, the Company’s lead product candidate, administered sequentially with decitabine, will be presented as a poster during the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on Monday, June 6, 2011. The treatment regimen under evaluation in this pilot study is being used as one of the arms in SEAMLESS, the registration-directed, Phase 3 study of sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia who are not candidates for intensive induction therapy.
